APA

Gaasterland C. M. W., Jansen-van der Weide M. C., Vroom E., Leeson-Beevers K., Kaatee M., Kaczmarek R., Bartels B., van der Pol W. L., Roes K. C. B. & van der Lee J. H. (20190528). The POWER-tool: Recommendations for involving patient representatives in choosing relevant outcome measures during rare disease clinical trial design. : Health policy (Amsterdam, Netherlands).

Chicago

Gaasterland C M W, Jansen-van der Weide M C, Vroom E, Leeson-Beevers K, Kaatee M, Kaczmarek R, Bartels B, van der Pol W L, Roes K C B and van der Lee J H. 20190528. The POWER-tool: Recommendations for involving patient representatives in choosing relevant outcome measures during rare disease clinical trial design. : Health policy (Amsterdam, Netherlands).

Harvard

Gaasterland C. M. W., Jansen-van der Weide M. C., Vroom E., Leeson-Beevers K., Kaatee M., Kaczmarek R., Bartels B., van der Pol W. L., Roes K. C. B. and van der Lee J. H. (20190528). The POWER-tool: Recommendations for involving patient representatives in choosing relevant outcome measures during rare disease clinical trial design. : Health policy (Amsterdam, Netherlands).

MLA

Gaasterland C M W, Jansen-van der Weide M C, Vroom E, Leeson-Beevers K, Kaatee M, Kaczmarek R, Bartels B, van der Pol W L, Roes K C B and van der Lee J H. The POWER-tool: Recommendations for involving patient representatives in choosing relevant outcome measures during rare disease clinical trial design. : Health policy (Amsterdam, Netherlands). 20190528.